Novocure Stock Fundamentals
| NVCR Stock | USD 18.44 0.33 1.76% |
Novocure fundamentals help investors to digest information that contributes to Novocure's financial success or failures. It also enables traders to predict the movement of Novocure Stock. The fundamental analysis module provides a way to measure Novocure's intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Novocure stock.
Novocure |
Novocure Company Return On Equity Analysis
Novocure's Return on Equity or ROE tells company stockholders how effectually their money is being utilized or reinvested. It is a useful ratio when analyzing company profitability or the management effectiveness given the capital invested by the shareholders. ROE shows how efficiently a company utilizes investments to generate income.
Current Novocure Return On Equity | -0.47 |
Most of Novocure's fundamental indicators, such as Return On Equity, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Novocure is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
For most industries, Return on Equity between 10% and 30% are considered desirable to provide dividends to owners and have funds for the future growth of the company. Investors should be very careful using ROE as the only efficiency indicator because ROE can be high if a company is heavily leveraged.
| Competition |
Based on the latest financial disclosure, Novocure has a Return On Equity of -0.4667. This is 98.05% lower than that of the Health Care Equipment & Supplies sector and 92.2% lower than that of the Health Care industry. The return on equity for all United States stocks is 50.55% higher than that of the company.
Novocure Fundamental Drivers Relationships
Comparative valuation techniques use various fundamental indicators to help in determining Novocure's current stock value. Our valuation model uses many indicators to compare Novocure value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across Novocure competition to find correlations between indicators driving Novocure's intrinsic value. More Info.Novocure is rated below average in return on equity category among its peers. It is rated below average in return on asset category among its peers . Comparative valuation analysis is a catch-all technique that is used if you cannot value Novocure by discounting back its dividends or cash flows. It compares the stock's price multiples to nearest competition to determine if the stock is relatively undervalued or overvalued.Novocure Return On Equity Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Novocure's direct or indirect competition against its Return On Equity to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Novocure could also be used in its relative valuation, which is a method of valuing Novocure by comparing valuation metrics of similar companies.Novocure is currently under evaluation in return on equity category among its peers.
Novocure Fundamentals
| Return On Equity | -0.47 | ||||
| Return On Asset | -0.0877 | ||||
| Profit Margin | (0.28) % | ||||
| Operating Margin | (0.39) % | ||||
| Current Valuation | 1.79 B | ||||
| Shares Outstanding | 109.92 M | ||||
| Shares Owned By Insiders | 9.70 % | ||||
| Shares Owned By Institutions | 84.85 % | ||||
| Number Of Shares Shorted | 5.2 M | ||||
| Price To Earning | 721.15 X | ||||
| Price To Book | 5.73 X | ||||
| Price To Sales | 3.59 X | ||||
| Revenue | 605.22 M | ||||
| Gross Profit | 469.04 M | ||||
| EBITDA | (109.58 M) | ||||
| Net Income | (168.63 M) | ||||
| Cash And Equivalents | 948.52 M | ||||
| Cash Per Share | 9.06 X | ||||
| Total Debt | 93.13 M | ||||
| Debt To Equity | 1.31 % | ||||
| Current Ratio | 8.08 X | ||||
| Book Value Per Share | 3.32 X | ||||
| Cash Flow From Operations | (26.37 M) | ||||
| Short Ratio | 5.65 X | ||||
| Earnings Per Share | (1.56) X | ||||
| Price To Earnings To Growth | (0.47) X | ||||
| Target Price | 35.57 | ||||
| Number Of Employees | 1.49 K | ||||
| Beta | 0.63 | ||||
| Market Capitalization | 2.17 B | ||||
| Total Asset | 1.24 B | ||||
| Retained Earnings | (1.15 B) | ||||
| Working Capital | 350.2 M | ||||
| Current Asset | 293.9 M | ||||
| Current Liabilities | 28.63 M | ||||
| Net Asset | 1.24 B |
About Novocure Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Novocure's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Novocure using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Novocure based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.NovoCure Limited, an oncology company, engages in the development, manufacture, and commercialization of tumor treating fields devices for the treatment of solid tumor cancers in the United States, Europe, the Middle East, Africa, Japan, and Greater China. NovoCure Limited was incorporated in 2000 and is headquartered in Saint Helier, Jersey. NovoCure operates under Medical Instruments Supplies classification in the United States and is traded on NASDAQ Exchange. It employs 1167 people.
Additional Tools for Novocure Stock Analysis
When running Novocure's price analysis, check to measure Novocure's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Novocure is operating at the current time. Most of Novocure's value examination focuses on studying past and present price action to predict the probability of Novocure's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Novocure's price. Additionally, you may evaluate how the addition of Novocure to your portfolios can decrease your overall portfolio volatility.